These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 22826485)
1. Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain. Navarro M; Norman FF; Pérez-Molina JA; López-Vélez R Am J Trop Med Hyg; 2012 Sep; 87(3):489-90. PubMed ID: 22826485 [TBL] [Abstract][Full Text] [Related]
2. Access to benznidazole for Chagas disease in the United States-Cautious optimism? Alpern JD; Lopez-Velez R; Stauffer WM PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005794. PubMed ID: 28910299 [TBL] [Abstract][Full Text] [Related]
3. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole. Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280 [TBL] [Abstract][Full Text] [Related]
5. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142 [TBL] [Abstract][Full Text] [Related]
6. An update on benznidazole for the treatment of patients with Chagas disease. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658 [TBL] [Abstract][Full Text] [Related]
7. [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America]. Chaves GC; Abi-Saab Arrieche M; Rode J; Mechali D; Reis PO; Alves RV; Stobbaerts E; Aguilar NG; Ribeiro I Rev Panam Salud Publica; 2017 Jun; 41():e45. PubMed ID: 28614468 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423 [TBL] [Abstract][Full Text] [Related]
9. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S; J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946 [TBL] [Abstract][Full Text] [Related]
10. New Approaches for the Treatment of Chagas Disease. Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855 [TBL] [Abstract][Full Text] [Related]
16. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Carrilero B; Murcia L; Martínez-Lage L; Segovia M Rev Esp Quimioter; 2011 Sep; 24(3):123-6. PubMed ID: 21947093 [TBL] [Abstract][Full Text] [Related]
17. Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review. Rev Inst Med Trop Sao Paulo; 2020; 62():e52err. PubMed ID: 32844906 [No Abstract] [Full Text] [Related]
18. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Alonso-Padilla J; Cortés-Serra N; Pinazo MJ; Bottazzi ME; Abril M; Barreira F; Sosa-Estani S; Hotez PJ; Gascón J Expert Rev Anti Infect Ther; 2019 Mar; 17(3):145-157. PubMed ID: 30712412 [TBL] [Abstract][Full Text] [Related]
19. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018. Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425 [TBL] [Abstract][Full Text] [Related]
20. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]